Biopharmaceuticals face competition in the atopic dermatitis sector.

According to industry sources, LEO Pharma’s Adtralza (tralokinumab), a treatment for atopic dermatitis with an underlying mechanism of neutralizing interleukin-13 (IL-13), is anticipated to launch with reimbursement starting in May.

Adtralza is the second biologic approved for atopic dermatitis, following Sanofi-aventis Korea’s 'Dupixent (dupilumab).'

Adtralza was approved in Korea last August and passed the review by the Drug Reimbursement Evaluation Committee (DREC) of the Health Insurance Review and Assessment Service (HIRA). The company recently completed price negotiations with the Nationa